Ralph Dornburg

Targeting Human T Cells by Retroviral Vectors Displaying Antibody Domains Selected from a Phage Display Library

To generate T cell-specific retroviral vectors an scFv phage display library derived from immunized mice was selected for binding to the human T cell line Molt-4/8. The scFv cDNAs recovered from the selected phages were transiently expressed as an N-terminal fusion of the spleen necrosis virus (SNV) transmembrane protein (TM) subunit of the viral envelope protein (Env) in the cell line DSH-cxl, which packages the beta-galactosidase gene into SNV particles. Screening of supernatants from about 150 transfections resulted in the identification of 5 scFvs that mediated efficient transduction of Molt-4/8 cells. Using stable packaging cell lines vector preparations with titers greater than 10(4) EFU/ml on human T cells were obtained. The scFv 7A5 in particular was able to mediate selective transduction of human T cells with high efficiency. Titers of up to 106 EFU/ml were reached on Molt-4/8, Jurkat, and A301 cells, while titers on HeLa cells, TE671 cells, 293T cells, and HT1080 cells were below 102 EFU/ml. Transduction of stimulated primary human peripheral blood cells, which consisted mainly of T cells, was about fivefold more efficient than transduction of B cells. Western blot analysis of supernatant from the 7A5 packaging cells demonstrated incorporation of 7A5-TM into vector particles and indicated proteolytic processing of the coexpressed unmodified TM during particle formation. Binding of bacterially expressed 7A5-scFv to a panel of cell lines correlated well with the transduction results. These data provide the first proof of concept that a general approach can be taken to obtain scFvs able to mediate selective gene transfer into target cells.

Spleen necrosis virus-derived C-type retroviral vectors for gene transfer to quiescent cells.

Gene therapy applications of retroviral vectors derived from C-type retroviruses have been limited to introducing genes into dividing target cells. Here, we report genetically engineered C-type retroviral vectors derived from spleen necrosis virus (SNV), which are capable of infecting nondividing cells. This has been achieved by introducing a nuclear localization signal (NLS) sequence into the matrix protein (MA) of SNV by site-directed mutagenesis. This increased the efficiency of infecting nondividing cells and was sufficient to endow the virus with the capability to efficiently infect growth-arrested human T lymphocytes and quiescent primary monocyte-derived macrophages. We demonstrate that this vector actively penetrates the nucleus of a target cell, and has potential use as a gene therapy vector to transfer genes into nondividing cells.

Cell-type-specific gene delivery into neuronal cells in vitro and in vivo

The avian retroviruses reticuloendotheliosis virus strain A (REV-A) and spleen necrosis virus (SNV) are not naturally infectious in human cells. However, REV-A-derived viral vectors efficiently infect human cells when they are pseudotyped with envelope proteins displaying targeting ligands specific for human cell-surface receptors. Here we report that vectors containing the gag region of REV-A and pol of SNV can be pseudotyped with the envelope protein of vesicular stomatitis virus (VSV) and the glycoproteins of different rabies virus (RV) strains. Vectors pseudotyped with the envelope protein of the highly neurotropic RV strain CVS-N2c facilitated cell type-specific gene delivery into mouse and human neurons, but did not infect other human cell types. Moreover, when such vector particles were injected into the brain of newborn mice, only neuronal cells were infected in vivo. Cell-type-specific gene delivery into neurons may present quite specific gene therapy approaches for many degenerative diseases of the brain.

HIV-I gene therapy: Promise for the future

Publisher Summary This chapter discusses the experimental genetic approaches to block HIV-1 replication and current gene-delivery techniques to transduce therapeutic genes into the precise target cells. Because the discovery that the acquired immunodeficiency syndrome (AIDS) is caused by HIV-1, several billion dollars have been invested worldwide to develop and test new pharmaceutical agents to control the spread of this epidemic disease. New conventional drugs are specifically designed to block the action of HIV-l-specific enzymes, such as the reverse transcriptase or the protease. Efforts are being made in many laboratories to develop alternative genetic approaches to inhibit the replication of this virus. With growing insight into the mechanism and regulation of HIV-1 replication, in the past decade, a large arsenal of genetic antivirals has been developed. Gene expression vectors have been constructed that express various antiHIV-1 products (RNAs or proteins) that attack basically every step in the viral life cycle. Tissue-culture cells have been transduced with such genes and it has been shown that such gene-transduced cells can become rather resistant to HIV-1 infection. It is unknown whether dormant viruses like HIV-1 can become active again late in the life of an HIV-l-infected individual and whether cells carrying antiHIV-1 antivirals would still be available and active to block reemerging viruses and reoccurring infections. Efficient gene-delivery tools are available at this point that would enable robust delivery to the actual target cell in vivo . Series of clinical trials and application of new findings have widened the scope to keep the promise for HIV-1 gene therapy in near future.

Cross-Packaging of Human Immunodeficiency Virus Type 1 Vector RNA by Spleen Necrosis Virus Proteins: Construction of a New Generation of Spleen Necrosis Virus-Derived Retroviral Vectors

ABSTRACT The ability of the nonlentiviral retrovirus spleen necrosis virus (SNV) to cross-package the genomic RNA of the distantly related human immunodeficiency virus type 1 (HIV-1) and vice versa was analyzed. Such a model may allow us to further study HIV-1 replication and pathogenesis, as well as to develop safe gene therapy vectors. Our results suggest that SNV can cross-package HIV-1 genomic RNA but with lower efficiency than HIV-1 proteins. However, HIV-1-specific proteins were unable to cross-package SNV RNA. We also constructed SNV-based gag-pol chimeric variants by replacing the SNV integrase with the HIV-1 integrase, based on multiple sequence alignments and domain analyses. These analyses revealed that there are conserved domains in all retroviral integrase open reading frames (orf), despite the divergence in the primary sequences. The transcomplementation assays suggested that SNV proteins recognized one of the chimeric variants. This demonstrated that HIV-1 integrase is functional in the SNV gag-pol orf with a lower transduction efficiency, utilizing homologous (SNV) RNA, as well as the heterologous vector RNA of HIV-1. These findings suggest that homology in the conserved sequences of the integrase protein may not be fully competent in the replacement of protein(s) from one retrovirus to another, and there are likely several other factors involved in each of the steps related to replication, integration, and infection. However, further studies to dissect the gag-pol region will be critical for understanding the mechanisms involved in the cleavage of reverse transcriptase, RNase H, and integrase. These studies should provide further insight into the design and development of novel molecular approaches to block HIV-1 replication and to construct a new generation of SNV-based vectors.

A Genetically Engineered Spleen Necrosis Virus-Derived Retroviral Vector That Displays the HIV Type 1 Glycoprotein 120 Envelope Peptide

We reported that SNV-derived retroviral vectors, which display single-chain antibodies on the viral surface, enable cell type-specific gene delivery into various human cells. In particular, the SNV cell type-specific gene delivery vector system appears to be well suited to transduce genes into cells of the human hematopoietic system (Jiang et al., J. Virol. 72:10148-10156, 1998). Here, we report the construction of SNV vector particles that display the complete gp120 surface unit of the envelope protein of human immunodeficiency virus type 1 (HIV-1) on the viral surface. The complete gp120-coding region of a T cell-tropic HIV-1 strain (LAI/BRU) was fused to a short peptide spacer coding region [(Gly4Ser)3] linking it to the SNV TM-coding region. The corresponding protein was expressed as a single 145-kDa peptide as expected. This peptide was nontoxic and could be stably expressed in dog D17 SNV-derived packaging cells. Particles harvested from stable packaging lines infected CD4+ human hematopoietic cells with titers exceeding 10(5) CFU/ml supernatant tissue culture medium. Titers in other, CD4- cell lines expressing various coreceptors of HIV-1 were 100-fold lower than titers obtained in CD4+ cells. Specificity of infection was demonstrated by antibody inhibition assays or by preincubating cells with SDF-1alpha, the ligand, which binds to the CXCR4 coreceptor, to which this gp120 binds. Our data indicate that binding of the HIV-1 gp120 to either CD4 or CXCR4 is sufficient to enable infection of human cells with SNV vector particles. We constructed retroviral vector particles that display chimeric HIV-1-SU-SNV-TM proteins plus wild-type SNV envelope on the viral surface. Such particles allowed efficient infection of CD4-positive human T lymphocytes, and, at a lower efficiency, also cells expressing CXCR4 without CD4. These data coincide with our earlier hypothesis that the chimeric envelope is required only to bind the vector particle to a cell surface receptor of the target cell, while membrane fusion is mediated by wild-type Env, which alone is not sufficient to enable infection of human cells.

Gene Therapy for HIV-1 Infection

Since the discovery that AIDS is caused by a retrovirus, HIV-1, enormous efforts have been made to develop new drugs that will combat this infectious disease. Although new conventional drugs have been found to block the replication of this virus efficiently, new mutant strains continuously arise, which escape the inhibitory effect of such drugs. Furthermore, since HIV-1 integrates its genome into that of the host cell, dormant viruses persist in infected individuals over long periods. Thus, great efforts are currently being made in many laboratories to develop alternative genetic approaches to inhibit the replication of this virus. With growing insight into the mechanism and regulation of HIV-1 replication, in the past decade, many strategies have been developed and proposed for clinical application to block HIV-1 replication inside the cell. Such strategies use either antiviral RNAs or proteins (for some recent reviews, see refs. 1–4). Antiviral strategies that employ RNAs have the advantage that they are less likely to be immunogenic than protein-based antiviral agents. However, protein-based systems have been engineered using inducible promoters that only become active upon HIV-1 infection. Although such antivirals have been proved to be very effective in vitro, their beneficial effect in vivo is very difficult to evaluate and still remains to be shown. In particular, the long latent period from infection to the onset of AIDS (up to 10 years or longer) makes it very difficult to evaluate the efficacy of a new drug.